Feature|Videos|July 9, 2025
Navigating Market Entry Challenges for Orphan Drugs
Edward Ahn, CEO of MEDIPOST, Inc., reacts to the challenge of launching orphan drugs without complete evidence, particularly given their high cost and limited patient populations, and suggests strategies that can be used to address evidence gaps, enable market access, and support long-term patient benefit.
Advertisement
Episodes in this series
Not every product has a perfect data set at launch, and that’s where risk-sharing and value-based contracts come into play. This episode explores examples of how companies structure these agreements to address uncertainty, while still ensuring access. With large populations, like with osteoarthritis patients, cost-effectiveness becomes a primary lever.
Key discussion topics include:
- The tradeoff between pricing and access in large populations.
- Examples of successful risk-sharing and subscription models.
- How to position therapies for payer engagement despite imperfect data.
- Why targeting measurable, cost-driven outcomes is critical.
Advertisement
Related to this article
Nuvera’s PURE Engagement research, built on feedback from more than 2,300 physicians and support staff, ranks 2026 patient support leaders by company size and therapeutic area.
Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.
Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.
In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.
Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.
ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand.
Inizio Ignite leaders argue static, milestone-driven launch plans fall short and AI sharpens execution only when built on a sound strategy.
Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Pharma Pulse: CVS Health to Break in Two, Bayer Weighs MFN
2
2026 Brought Progress on Drug Prices. What Will It Take to Improve Patient Access in 2027?
3
Big Three Distributors Lean on Specialty for Profit Growth
4
The System-Level View That Sound Market Access Decisions Are Missing
5